Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2009 1
2010 1
2012 2
2013 2
2014 1
2015 2
2017 3
2018 2
2019 3
2020 5
2021 11
2022 11
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
The Information Technology (IT) Infrastructure of the Multicenter Archipelago of Ovarian Cancer Research Biobank: A Potential Blueprint for Other Biobanks.
Zelisse HS, de Ridder S, van Gent MDJM, Mom CH, Wisman GBA, Roes EM, Reyners AKL, Piek JM, Nieuwenhuyzen-de Boer GM, Lok CAR, de Kroon CD, Kooreman LFS, Janssen MJ, Jansen MP, Horlings HM, Collée M, Broeks A, Boere IA, Bart J, van Altena AM, Heeling M, Stoter IM, Voorham QJ, van de Vijver MJ, Dijk F, Belien JAM; Archipelago of Ovarian Cancer Research Consortium. Zelisse HS, et al. Among authors: boere ia. Biopreserv Biobank. 2024 Apr 29. doi: 10.1089/bio.2023.0118. Online ahead of print. Biopreserv Biobank. 2024. PMID: 38682281
RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
Charnalia M, Chopra S, Mulani J, Popat P, Rath S, Thomeer M, Mittal P, Gupta A, Boere I, Gupta S, Nout RA. Charnalia M, et al. Among authors: boere i. Int J Gynecol Cancer. 2024 Apr 22:ijgc-2024-005336. doi: 10.1136/ijgc-2024-005336. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38649234
Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer.
Xu T, Verhagen MP, Teeuwssen M, Sun W, Joosten R, Sacchetti A, Ewing-Graham PC, Jansen MPHM, Boere IA, Bryce NS, Zeng J, Treutlein HR, Hook J, Hardeman EC, Gunning PW, Fodde R. Xu T, et al. Among authors: boere ia. Cell Death Differ. 2024 Mar;31(3):360-377. doi: 10.1038/s41418-024-01267-9. Epub 2024 Feb 16. Cell Death Differ. 2024. PMID: 38365970 Free PMC article.
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
van der Ploeg P, Hendrikse CS, Thijs AM, Westgeest HM, Smedts HP, Vos MC, Jalving M, Lok CA, Boere IA, van Ham MA, Ottevanger PB, Westermann AM, Mom CH, Lalisang RI, Lambrechts S, Bekkers RL, Piek JM. van der Ploeg P, et al. Among authors: boere ia. Heliyon. 2023 Dec 1;10(1):e23170. doi: 10.1016/j.heliyon.2023.e23170. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187310 Free PMC article.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: boere ia. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, Cibula D, Tewari KS, Madsen K, Köse F, Jackson AL, Boere IA, Scambia G, Randall LM, Sadozye A, Baurain JF, Gort E, Zikán M, Denys HG, Ottevanger N, Forget F, Mondrup Andreassen C, Eaton L, Chisamore MJ, Viana Nicacio L, Soumaoro I, Monk BJ. Vergote I, et al. Among authors: boere ia. J Clin Oncol. 2023 Dec 20;41(36):5536-5549. doi: 10.1200/JCO.23.00720. Epub 2023 Aug 31. J Clin Oncol. 2023. PMID: 37651655 Free PMC article. Clinical Trial.
CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X. Karamouza E, et al. Among authors: boere ia. Cancers (Basel). 2023 Mar 17;15(6):1823. doi: 10.3390/cancers15061823. Cancers (Basel). 2023. PMID: 36980708 Free PMC article.
54 results